QIAGEN and NVIDIA partner on AI drug discovery

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases

Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal

SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization

Bristol Myers Squibb & Anthropic redraw biopharma with Claude-powered enterprise AI

BMS is moving beyond conversational AI into what it describes as “agentic” systems

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Glenmark Pharma introduces Vancomycin Injection in U.S. market

The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.

Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care

The target reach is of more than 30 million young people and caregivers across 21 countries